Influenza
Conditions
Brief summary
* To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses. * To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age. * To describe the genotypic and phenotypic stability of shed vaccine viruses. * To describe the immune responses of FluMist in individuals 5-49 years of age. * To describe the safety of FluMist in individuals 5-49 years of age in relation to shedding and the immune response
Detailed description
The purpose of this study is to evaluate the viral shedding, immunogenicity and safety of FluMist when administered to healthy individuals between 5-49 years of age.
Interventions
BIOLOGICALFluMist
A single intranasal dose of FluMist will be administered to approx. 300 subjects.
Sponsors
MedImmune LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
5 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
* 5-49 years of age; * In good health; * Individual or parent/guardian available by telephone; * Ability of the participant or parent/guardian to understand and comply with the requirements of the protocol; and * Signed informed consent and HIPAA authorization by the participant or parent/guardian.
Exclusion criteria
* History of hypersensitivity to any component of FluMist, including egg or egg products; * History of hypersensitivity to gentamicin; * Close contact who is immunocompromised within the same household; * Known or suspected immune deficiency diseases or immunosuppressed or have altered or compromised immune status as a consequence of treatment with immunosuppressive therapies; * History of chronic underlying medical conditions such as chronic disorders of the cardiovascular and pulmonary systems, chronic metabolic diseases (including diabetes), renal dysfunction, or hemoglobinopathies; * History of Guillain-Barré syndrome; * History of asthma or reactive airways disease; * Acute febrile (\>100.0°F oral) and/or respiratory illness, within the 72 hours prior to enrollment; * For children and adolescents - use of aspirin or aspirin containing products in the month prior to enrollment or anticipated use during the study; * Pregnancy or, in biologically capable women (e.g., menses within the last year), not willing to agree to acceptable birth control for three months after enrolling into the study (for those biologically capable, a urine pregnancy test must be performed on the day of vaccination with a negative result); * Administration of any intranasal medication within two weeks prior to enrollment or expected receipt during this study; * Administration of any live virus vaccine within one month prior to enrollment or if receipt of another live virus vaccine is expected within one month of the vaccination in this study; * Administration of any inactivated vaccine within two weeks prior to enrollment or if receipt of another inactivated vaccine is expected within two weeks of the vaccination in this study; * Participation in another investigational trial or administration of any investigational drug within one month prior to enrollment or during this study; * Employees of the research center, any individuals involved with the conduct of the study, or any family member of such individuals; * Laboratory confirmed influenza (positive culture or rapid antigen test) in the prior influenza season (2003/2004 or 2004/2005 season); * Receipt of any influenza vaccine in the prior influenza season; and * Any condition that in the opinion of the investigator would interfere with the interpretation or evaluation of the vaccine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses. | 28 days after vaccination |
| To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age. | 28 days after vaccination |
Secondary
| Measure | Time frame |
|---|---|
| To describe the immune responses of FluMist in indivduals 5-49 years of age. | 28 days after vaccination |
| To describe the safety of FluMist in individuals 5-49 years of age in relation to shedding and the immune response. | 28 days after vaccination |
Countries
United States
Outcome results
None listed